ada standards of care (2025): pharmacologic approaches to glycemic treatment MCQ (SBA): Type 2 Diabetes Mellit

Instant feedback + full explanation. One question, done properly.

MediumDPP-4 inhibitorsType 2 Diabetes Mellitus with ASCVD riskada standards of care (2025): pharmacologic approaches to glycemic treatment

A 55-year-old man with new diabetes and BMI 31 has A1C 7.6% despite metformin. ASCVD risk 8%. Which initial add-on prioritizes weight loss and CV benefit?

Educational content. Not a substitute for clinical judgement or local policy.

ada standards of care (2025): pharmacologic approaches to glycemic tre